Denosumab (Xgeva/Prolia and biosimilars) Medicare coverage criteria
Customize your policy alerts
Sign up for Aloha Care Policy RXMP-39 alerts
Get alerted when Policy RXMP-39 changes without checking for updates manually.
Monitor payer policy activity
Medicare (and Medicaid) prior authorization, quantity limits, preferred biosimilars, and clinical approval/renewal criteria for denosumab products (Xgeva/Prolia and listed biosimilars) provided under Aloha Care Medicare benefit.
Adopt Optum Health's Denosumab and Biosimilars, Cancer Related Indications, 12/5/2025.
Coverage and Medical Necessity Criteria
Medicare/Medicaid denosumab approval criteria
Clinical approval and renewal criteria for Xgeva and denosumab biosimilars for listed oncology and bone indications.
Step therapy requirement applies except during Medicare 90-day transition for new members.
Cancer-related indications criteria
Initial and renewal coverage criteria by indication
Renewal for ADT-associated bone loss
Renewal and indication-related criteria excerpts and contextual clinical thresholds drawn from the policy text in this segment.
ALL of the following
- Member is receiving androgen deprivation therapy.
- Documentation of positive clinical response to therapy.
- Dosing is in accordance with United States Food and Drug Administration approved labeling.
- Authorization is limited to no more than 12 months.
Coverage and clinical criteria summary
Coverage considerations reference FDA-labeled indications and NCCN guideline recommendations; Medicare may cover Part B-administered denosumab when furnished incident to a physician's service and when consistent with benefit rules.
Cancer-related indications (ICD-10 mappings)
Lists cancer-related diagnoses and ICD-10 codes that map to denosumab and biosimilar coverage considerations.
Policy includes additional C79.x secondary malignancy codes (see code list).
Indication groupings and criteria shortcuts
Criteria shortcuts and indication groupings are listed to simplify review for commonly requested oncology and bone indications.
Initial Authorization Requirements
Initial therapy criteria
Initial authorization requirements
Initial therapy criteria
Initial criteria common elements
INITIAL THERAPY CRITERIA
Typical initial dosing regimens discussed in clinical trials.
Renewal and Continuation Requirements
Renewal/Continuation criteria — Renewal requirements
Renewal/continuation requests are approved only when ALL of the following renewal conditions are met:
ALL of the following
- Member is receiving appropriate disease-specific systemic therapy (e.g., androgen deprivation therapy for prostate cancer) and documentation of ongoing therapy is provided
- Documentation of positive clinical response to therapy is submitted (clinical assessment or objective evidence)
- Dosing is in accordance with United States FDA–approved labeling for the requested denosumab product
- Authorization/approval length for the renewal request is for no more than 12 months
See indication-specific renewal sections for any additional required elements (for example, continued androgen-deprivation therapy for prostate cancer or continued aromatase inhibitor therapy for breast cancer)
Renewal criteria — Renewal criteria common elements
Common elements required for renewal of denosumab (all indications where renewal is applicable):
ALL of the following
- Documentation that member remains on the relevant systemic therapy associated with the original indication (e.g., androgen deprivation therapy for prostate cancer; aromatase inhibitor for breast cancer)
- Clinical documentation of positive treatment response or continued clinical benefit since initiation (progress notes, imaging, laboratory results as appropriate)
- Dosing and administration records demonstrating treatment consistent with FDA-approved labeling for the specific denosumab product requested
- Authorization requests (initial and renewal) will be approved for periods up to 12 months per authorization; provider should request renewal annually as needed
Documentation regarding prior bisphosphonate therapy (where required by indication)
- Evidence of intolerance, contraindication (including significant renal insufficiency), or failure of intravenous bisphosphonate therapy (e.g., pamidronate, zoledronic acid) within the prior 30 days when the indication specifies this requirement
- If the indication permits, documentation of prior oral bisphosphonate intolerance may be accepted when consistent with the specific initial criteria for that diagnosis
Authorization length and administrative notes
- Standard approval length for initial and renewal requests: up to 1 year (12 months). Providers should submit renewal requests with supporting documentation of continued benefit
- Medicare Part B 90-day transition: for new Medicare members on an active course of denosumab, coverage and step-therapy requirements do not apply during the first 90 days after enrollment (refer to transition policy)
Continuation interpretation from long-term data: FREEDOM extension post-hoc analyses demonstrated lower subsequent osteoporotic fracture incidence while continuing denosumab (up to 10 years) compared with placebo; this evidence may inform clinical decisions regarding ongoing therapy but renewal still requires the documentation elements above
Denosumab and biosimilars — cancer indications: refer to the cancer-related indication groupings and required documentation for indication-specific renewal rules (header: Denosumab and biosimilars, Cancer Related Indications)
Continuation data (FREEDOM extension) — Long-term extension data and interpretation regarding continuation of denosumab therapy
Long-term continuation interpretation based on extension study data (FREEDOM extension):
ALL of the following
- Post-hoc FREEDOM extension data show a lower exposure-adjusted incidence of subsequent osteoporotic fractures for subjects continuing denosumab (combined denosumab up to 10 years) compared with placebo (hazard ratio 0.59, 95% CI 0.43–0.81; p=0.0012)
- These extension data support that continued denosumab treatment may reduce risk of subsequent fractures versus discontinuation; however, continuation approvals still require the renewal documentation and authorization length limits stated in the policy
Renewal requirements for ADT-associated bone loss
Renewal requires the member to be receiving androgen deprivation therapy, to have documentation of a positive clinical response to therapy, dosing that is in accordance with FDA‑approved labeling, and authorization is limited to no more than 12 months.
Billing Codes and Diagnosis Mapping
| J0897 | Injection, denosumab, 1 mg (Prolia/Xgeva) |
| C9399 | Injection, denosumab-nxxp (Bildyos/Bilprevda), biosimilar, 1 mg |
| Q5158 | Injection, denosumab-bhntz (Conexxence/Bomyntra), biosimilar, 1 mg |
| Q5136 | Injection, denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg (preferred) |
| Q5157 | Injection, denosumab-bmwo (Stoboclo/Osenvelt), biosimilar, 1 mg (preferred) |
| Q5159 | Injection, denosumab-dssb (Ospomyv/Xbryk), biosimilar, 1 mg |
| No codes listed |
| M81.8 | Other osteoporosis without current pathological fracture |
| M80.811A | Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture |
| M80.839A | Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture |
| M80.839D | Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with routine healing |
| M80.841A | Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture |
| M80.851A | Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture |
| M80.88XA | Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture |
| Z78.310 | Personal history of (healed) osteoporosis fracture |
| C61 | Malignant neoplasm of prostate |
| C79.51 | Secondary malignant neoplasm of bone |
| C79.52 | Secondary malignant neoplasm of bone marrow |
| C90.00 | Multiple myeloma not having achieved remission |
Prior Authorization, Documentation, and Operational Guidance
Prior authorization and coding required
Prior authorization is required for denosumab products (HCPCS J0897 and listed biosimilar Q-codes); Medicare/Medicaid preferred biosimilars include Wyost and Osenvelt. Authorization/coverage decisions reference these codes and preferred status.
Medicare Part B 90-day transition: exemptions for active treatment
A 90-day Medicare Part B transition period applies for new Medicare members on an active course of treatment; during those 90 days Coverage and Step Therapy requirements do not apply. After 90 days, policy criteria must be met for continued coverage.
- Transition period: first 90 days of Medicare enrollment
- Coverage and Step Therapy suspended during active treatment in transition window
Authorization length: initial and renewal = 1 year
Authorizations (initial and renewal) are required and approvals are issued for up to one year (authorization limited to no more than 12 months).
- Approval length: Initial/Renewal Request = 1 year
- Authorization required
Formulary preference and step requirements
Preferred agents may be approved when criteria are met. For non-preferred agents, the member must have tried and failed two preferred agents from each drug class (or one if only one preferred exists) before non-preferred approval.
- Preferred agent approval permitted if criteria met
- Non-preferred: trial/failure of 2 preferred agents per class (or 1 if only one preferred exists)
Document prior IV bisphosphonate failure/contraindication/intolerance
For several indications (e.g., hypercalcemia of malignancy, systemic mastocytosis, giant cell tumor of bone), documentation must show refractory (within the past 30 days), contraindication (including renal insufficiency), or intolerance to intravenous bisphosphonate therapy (e.g., pamidronate, zoledronic acid).
- Refractory to IV bisphosphonates within past 30 days
- Or documented contraindication (including renal insufficiency)
- Or documented intolerance to IV bisphosphonates
Dosing must follow FDA-approved labeling
Dosing for denosumab must be in accordance with United States FDA–approved labeling for the specific indication.
- Follow FDA-approved dosing per indication (e.g., Prolia 60 mg Q6M; Xgeva 120 mg monthly where applicable)
Medicare Part B coverage context for outpatient administration
Medicare may cover outpatient (Part B) drugs furnished 'incident to' a physician's service when the drugs are not usually self-administered; refer to Medicare Benefit Policy Manual, Chapter 15, Section 50 and applicable LCDs/LCAs for coverage details.
- Part B coverage may apply when drugs are furnished 'incident to' and not usually self-administered
- No NCD specific to denosumab; check applicable LCDs/LCAs
Denosumab and biosimilars — cancer-related indications
Denosumab (Xgeva) and listed biosimilars are addressed under the policy for cancer-related indications (prevention of skeletal-related events, giant cell tumor of bone, hypercalcemia of malignancy) and are subject to the authorization and clinical criteria in this section.
- Indications include hypercalcemia of malignancy, giant cell tumor of bone, and prevention of SREs in metastatic disease
- Products listed for cancer-related indications include Bilprevda, Bomyntra, Osenvelt (preferred), Wyost (preferred), Xgeva, Xbryk
Adoption notice: Optum Health guidance adopted
The policy adopts Optum Health's 'Denosumab and Biosimilars, Cancer Related Indications' guidance (12/5/2025), which updated prior authorization criteria for cancer-related denosumab indications.
- Change history: adoption of Optum Health guidance dated 12/5/2025
Key Terms and Definitions
Step Therapy and Trial Requirements
| Rule | Details |
|---|---|
| Step-therapy applies for new starts | |
| For denosumab (Xgeva) and biosimilars, step-therapy is required for new starts except during the Medicare Part B 90-day transition period for new members; members on an active course of treatment during the first 90 days are not subject to step therapy | |
| Preferred-agent-first requirement | |
| A preferred biosimilar (examples: Osenvelt or Wyost) may be approved if the member meets clinical criteria; new starts must try preferred agents first per policy | |
| Prior therapy requirement | |
| New-start denosumab requires inadequate response to or contraindication to an injectable bisphosphonate (e.g., pamidronate, zoledronic acid) AND trial/failure of one of the preferred biosimilars (e.g., Osenvelt or Wyost) |
| Requirement | Policy detail |
|---|---|
| Trial and failure prior to non-preferred approval | |
| For non-preferred denosumab products, the member must have tried and failed 2 preferred agents from each drug class; if only one preferred agent exists, failure of that one preferred agent is sufficient | |
| Age / population applicability | |
| Applies across indicated populations (e.g., adults or skeletally mature adolescents where specified); preferred/non-preferred rules are included in initial criteria for all indications | |
| Documentation of bisphosphonate intolerance/failure | |
| Where indicated (e.g., hypercalcemia of malignancy, systemic mastocytosis), documentation of refractory/contraindication/intolerance to IV bisphosphonates within the prior 30 days is required as part of the approval pathway for non-preferred agents |
Quantity Limits and Dosing Examples
Infusion center administration and Part B billing
Outpatient administration under Medicare Part B may be furnished in an infusion/clinic setting 'incident to' a physician's service when drugs are not usually self-administered; ensure billing aligns with Part B rules for such settings.
- Site of care: infusion center/office when furnished 'incident to' physician service
- Confirm Part B billing rules and LCD/LCAs as applicable
Preferred Agents and Biosimilar Coding
Preferred biosimilars for Medicare/Medicaid
For Medicare and Medicaid reviews, Xgeva (denosumab) and listed biosimilars (including Wyost and Osenvelt) are identified as preferred agents for cancer-related indications.
- Preferred biosimilars named: Wyost, Osenvelt
- Products listed: Bilprevda, Bomyntra, Osenvelt (preferred), Wyost (preferred), Xgeva, Xbryk
Use preferred denosumab products when meeting criteria
Xgeva and several biosimilars are enumerated as preferred products for cancer-related indications; providers should use preferred biosimilars when criteria are met to support coverage.
- HCPCS/Q-codes listed for denosumab and biosimilars (see policy code table)
- Using preferred biosimilars supports approval when criteria are satisfied
Document product and code for cancer-related denosumab requests
Xgeva and other denosumab products (including Osenvelt and Wyost) are listed among preferred products for cancer-related indications; document product selection in the authorization request.
- List of preferred and listed products appears in the policy's cancer-related section
- Include product name and HCPCS/Q-code in PA submission
Reference cancer-related criteria and ICD-10 codes in PA
Xgeva and listed biosimilars are recognized in the policy's cancer-related indications; when requesting coverage, reference the cancer-related criteria and include supporting documentation as required.
- Indications and ICD-10 mappings are provided in the cancer-related section
- Attach relevant diagnosis codes and clinical documentation with PA
Reference prescribing information and adopted guidance in requests
Denosumab products (Prolia, Xgeva) and multiple biosimilars are cited with prescribing information; providers should reference relevant prescribing information and the policy when requesting coverage.
- Policy cites multiple biosimilar prescribing information entries
- Adoption of external guidance (Optum Health) reflected in change history
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.